Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22868175 | 0.77 | RIPK1 (0.31) | — | |
| SCHEMBL11655814 | 0.77 | — | — | |
| SCHEMBL20063361 | 0.77 | — | — | |
| SCHEMBL24256512 | 0.77 | CHRM2 (0.34) | — | |
| SCHEMBL17854740 | 0.77 | MEN1 (0.30) | MEN1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL24507340 | 0.77 | — | — | |
| SCHEMBL1106444 | 0.76 | — | — | |
| SCHEMBL19091449 | 0.73 | MEN1 (0.34) | MEN1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL16944043 | 0.73 | ALDH1A1 (0.39) | MEN1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL12591096 | 0.73 | ALDH1A1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834413-B2 | Antiplatelet drugs and uses thereof | SHANGHAI CUREGENE PHARMACEUTICAL CO LTD. (CN) | 2023-12-05 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230302091-A1 | Combination Therapy with Controlled-Release CNP Agonists | ASCENDIS PHARMA GROWTH DISORDERS AS (DK) | 2023-09-28 | — | — | US | disclosed |
| US-20230295089-A1 | ANTIPLATELET DRUGS AND USES THEREOF | SHANGHAI CUREGENE PHARMACEUTICAL CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230255950-A1 | 3-(Hydroxy)-Pyridin-4(1H)-One Compounds and Methods of Making and Using the Same | GEORGIA TECH RESEARCH CORPORATION | 2023-08-17 | — | — | US | disclosed |
| US-20230255950-A1 | 3-(Hydroxy)-Pyridin-4(1H)-One Compounds and Methods of Making and Using the Same | GEORGIA TECH RESEARCH CORPORATION | 2023-08-17 | — | — | US | disclosed |
| US-20230250089-A1 | MAP4K3 SMALL MOLECULE DRUG INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-08-10 | — | — | US | disclosed |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11667613-B2 | Antiviral pyrazolopyridinone compounds | NOVARTIS AG (CH) | 2023-06-06 | — | — | US | disclosed |
| US-20120115864-A1 | Substituted Fused Pyrimidine Compounds | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-05-10 | — | — | US | disclosed |
| US-20110224208-A1 | NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2011-09-15 | — | — | US | disclosed |
| US-7947708-B2 | Compounds modulating C-kit activity | PLEXXIKON, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20110077237-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-31 | — | — | US | disclosed |
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | NISSAN CHEMICAL INDUSTRIES LIMITED | 2010-11-11 | — | — | US | disclosed |
| US-20090264496-A1 | Compounds, Compositions and Methods for Making the Same | SIGNUM BIOSCIENCES, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
| US-7494714-B2 | Surfaces that resist the adsorption of biological species | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 2009-02-24 | — | — | US | disclosed |
| US-20070264505-A1 | Resistant to the adsorption of proteins, cells and bacteria; have a chemical chain bonded thereon that comprise a terminal group free of a hydrogen bond donor or where a hydrogen bond donor is sufficiently buried | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-11-15 | — | — | US | disclosed |
| US-7276286-B2 | Surfaces that resist the adsorption of biological species | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 2007-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255950-A1 | 3-(Hydroxy)-Pyridin-4(1H)-One Compounds and Methods of Making and Using the Same | KDM1B, KDM3A, KDM1A | MEN1 1552/4885CYP3A4 2183/4885CYP2C9 3689/4885 |
| US-20090264496-A1 | Compounds, Compositions and Methods for Making the Same | PPP2CA, PPP4C, PPP6C | MEN1 3072/4885CYP3A4 3267/4885CYP2C9 4067/4885 |
| US-20090124602-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | MEN1 1427/4885CYP3A4 3450/4885CYP2C9 3533/4885 |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | MEN1 139/4885CYP3A4 263/4885CYP2C9 210/4885 |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | MEN1 1035/4885CYP3A4 57/4885CYP2C9 51/4885 |
| US-11834413-B2 | Antiplatelet drugs and uses thereof | PFKP, GP6, PF4 | MEN1 2835/4885CYP3A4 2072/4885CYP2C9 1891/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | MEN1 1035/4885CYP3A4 57/4885CYP2C9 51/4885 |
| US-20230250089-A1 | MAP4K3 SMALL MOLECULE DRUG INHIBITORS AND METHODS OF USE THEREOF | MAP4K3, MAP3K4, MAP3K3 | MEN1 2811/4885CYP3A4 2493/4885CYP2C9 4601/4885 |
| US-20110224208-A1 | NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION | MAVS, IRF3, EIF2AK2 | MEN1 4759/4885CYP3A4 722/4885CYP2C9 2412/4885 |
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | P2RY1, P2RX7, P2RX1 | MEN1 3931/4885CYP3A4 830/4885CYP2C9 1174/4885 |
| US-20230295089-A1 | ANTIPLATELET DRUGS AND USES THEREOF | PFKP, GP6, PF4 | MEN1 2835/4885CYP3A4 2072/4885CYP2C9 1891/4885 |
| US-11667613-B2 | Antiviral pyrazolopyridinone compounds | ZC3HAV1, TYMP, ZC3HAV1L | MEN1 1512/4885CYP3A4 198/4885CYP2C9 245/4885 |
| US-20120115864-A1 | Substituted Fused Pyrimidine Compounds | ADORA2A, ADORA1, ADORA3 | MEN1 4851/4885CYP3A4 1199/4885CYP2C9 2056/4885 |
| US-20230302091-A1 | Combination Therapy with Controlled-Release CNP Agonists | CNP, NPR1, NGF | MEN1 1072/4885CYP3A4 4769/4885CYP2C9 4681/4885 |
| US-20110077237-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | MEN1 1427/4885CYP3A4 3450/4885CYP2C9 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.